Structure-based screening and identification of a novel Aurora-A-targeting peptide with antiproliferative activity against prostate cancer cells.
Peptide-1 shows potential as an Aurora-A-targeting peptide with antiproliferative effects in prostate cancer cell lines, but clinical relevance is not established.
Where it sits
this study against the rest of the p21 (p021) corpusSummary and findings
This study evaluated the antiproliferative activity of Peptide-1 against prostate cancer cells, specifically PC3, DU145, and NCI-H660. The peptide demonstrated a binding affinity towards Aurora-A with a Kd of 0.72 ± 0.04 μM. Not reported in abstract.
Abstract
Aurora-A is a potential therapeutic target in prostate cancer. In this study, virtual screening identified four Aurora-A-targeting peptides, among which Peptide-1 showed the most favourable profile. Molecular docking and MST assays demonstrated that Peptide-1 had the lowest predicted binding free energy and the strongest binding affinity towards Aurora-A (<i>K</i><sub>d</sub> = 0.72 ± 0.04 μM). MD simulation, MM/PBSA, and free-energy landscape analyses indicated that the Aurora-A-Peptide-1 complex was conformationally stable and mainly driven by electrostatic interactions. MTT assays showed that Peptide-1 inhibited the proliferation of PC3, DU145, and NCI-H660 cells, with weaker activity in RWPE-1 cells. Aurora-A knockdown reduced cellular sensitivity to Peptide-1, supporting its target-dependent activity. qRT-PCR further showed increased p53 and p21 mRNA expression after Peptide-1 treatment in PC3/p53WT cells. These findings suggest that Peptide-1 may act as an Aurora-A-targeting peptide with antiproliferative activity in prostate cancer cells.
Background
Aurora-A is implicated as a therapeutic target in prostate cancer, with prior studies suggesting its role in cell proliferation. This study aims to identify and characterize a novel peptide that targets Aurora-A, potentially offering a new avenue for treatment. Understanding the binding affinity and activity of such peptides could inform future therapeutic strategies.
Methods
The study utilized virtual screening to identify Aurora-A-targeting peptides, focusing on Peptide-1. Molecular docking and MST assays were performed to assess binding affinity, with a specific focus on Kd values. MTT assays evaluated the antiproliferative effects of Peptide-1 on various prostate cancer cell lines, and qRT-PCR assessed mRNA expression levels.
Results
Peptide-1 exhibited a binding affinity of Kd = 0.72 ± 0.04 μM towards Aurora-A. The peptide inhibited the proliferation of PC3, DU145, and NCI-H660 cells, with reduced activity noted in RWPE-1 cells. Aurora-A knockdown experiments indicated a decrease in sensitivity to Peptide-1, and qRT-PCR results showed increased p53 and p21 mRNA expression in PC3/p53WT cells post-treatment.
Interpretation
The findings suggest that Peptide-1 effectively binds to Aurora-A and inhibits cancer cell proliferation, aligning with previous literature on Aurora-A's role in cancer. However, while the binding affinity is statistically significant, the clinical relevance remains uncertain without human data. Limitations such as reliance on in vitro models and the absence of clinical trials may confound the applicability of these results in practice.
Key findings
- Kd = 0.72 ± 0.04 μM for Peptide-1 binding to Aurora-A.
- Peptide-1 inhibited proliferation of PC3, DU145, and NCI-H660 cells.
- Weaker activity of Peptide-1 was observed in RWPE-1 cells.
- Aurora-A knockdown reduced cellular sensitivity to Peptide-1.
- Increased p53 and p21 mRNA expression after Peptide-1 treatment in PC3/p53WT cells.
Limitations
- In vitro study, no human data provided.
- Small sample sizes in cell line experiments.
- Lack of long-term follow-up data.
- No clinical trials reported.